Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.

ABSTRACT:

Context

Agitation and psychosis are common in Alzheimer disease and cause considerable morbidity. We attempted to delay or to prevent agitation and psychosis with the use of divalproex sodium (valproate).

Objective

To determine whether treatment with valproate could delay or prevent emergence of agitation or psychosis.

Design, setting, and patients

A multicenter, randomized, double-blind, placebo-controlled trial of flexible-dose valproate in 313 (of 513 screened) individuals with moderate Alzheimer disease who had not yet experienced agitation or psychosis. The study was conducted from November 1, 2005, through March 31, 2009, at 46 sites in the United States.

Intervention

Participants were randomly assigned to valproate treatment at a target dose of 10 to 12

SUBMITTER: Tariot PN 

PROVIDER: S-EPMC7003728 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature